Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab

Social Author Image

https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3_normal.jpg

Tweet Author

Social Author Name

Richard Conway

Tweet Content

Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab significantly better at week 12 but no longer at week 24. @RheumNow #ACR24 Abstr#1457 https://t.co/4TGSiUPebV https://t.co/eAANkYIpzy

Links

Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab vers… https://acrabstracts.org/abstract/treat-to-target-approaches-in-early-psoriatic…

https://x.com/RichardPAConway/status/1858190864708780251/photo/1

Show on Archive Page

On

Display in Search Results

On

PDQ

Off

Topics

Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab

Do you get our email newsletter?